Immunogenicity and safety of single‐dose, 13‐valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30764
Abstract: Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13‐valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is an absence of literature regarding… read more here.
Keywords: conjugate vaccine; valent pneumococcal; oncology; pneumococcal conjugate ... See more keywords
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis
Sign Up to like & getrecommendations! Published in 2024 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-024-00977-4
Abstract: Since 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany’s Standing Committee on Vaccinations for infants, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce… read more here.
Keywords: pneumococcal conjugate; disease; pcv20; conjugate vaccine ... See more keywords
Impact of pneumococcal conjugate vaccines on otitis media: A review of measurement and interpretation challenges.
Sign Up to like & getrecommendations! Published in 2017 at "International journal of pediatric otorhinolaryngology"
DOI: 10.1016/j.ijporl.2017.07.009
Abstract: Acute otitis media (AOM) is among the most frequent childhood diseases and is caused by various bacterial and viral etiological agents. In this article, we provide an overview of published studies assessing the impact of… read more here.
Keywords: otitis media; vaccines otitis; pneumococcal conjugate; impact pneumococcal ... See more keywords
Impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on acute mastoiditis in children in southern Israel: A 12-year retrospective comparative study (2005-2016).
Sign Up to like & getrecommendations! Published in 2020 at "International journal of pediatric otorhinolaryngology"
DOI: 10.1016/j.ijporl.2020.110485
Abstract: OBJECTIVES To define the trends in acute mastoiditis (AM) incidence, microbiology, complications and management in children, before and after the 13-valent pneumococcal conjugate vaccine (PVC13) introduction. METHODS Medical records of all AM patients read more here.
Keywords: acute mastoiditis; study; conjugate vaccine; valent pneumococcal ... See more keywords
Childhood meningitis in Kuwait in the era of post pneumococcal conjugate vaccination: A multicenter study.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of infection and public health"
DOI: 10.1016/j.jiph.2016.11.009
Abstract: This is a retrospective study to evaluate epidemiology and etiologies of childhood meningitis in Kuwait after the routine introduction of the pneumococcal conjugate vaccine. The data was collected from 196 patients in the period of… read more here.
Keywords: meningitis; childhood meningitis; meningitis kuwait; era post ... See more keywords
Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2016.12.070
Abstract: Objective The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness… read more here.
Keywords: vaccination mongolia; cost effectiveness; valent pneumococcal; vaccination ... See more keywords
Timeliness and risk factors associated with delay for pneumococcal conjugate 10-valent routine immunization in Brazilian children.
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2017.01.012
Abstract: BACKGROUND Vaccination coverage is the usual metrics to evaluate the immunization programs performance. For the 10-valent pneumococcal conjugate (PCV10) vaccine, measuring the delay of vaccination is also important, particularly as younger children are at increased… read more here.
Keywords: risk; immunization; age; vaccination ... See more keywords
Pneumococcal carriage among children after four years of routine 10-valent pneumococcal conjugate vaccine use in Brazil: The emergence of multidrug resistant serotype 6C.
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2017.04.019
Abstract: BACKGROUND In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced free of charge in Brazil as part of the public immunization program. Here we investigated the carriage prevalence, colonization risk factors, capsular types, and… read more here.
Keywords: use; conjugate vaccine; valent pneumococcal; carriage ... See more keywords
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
Sign Up to like & getrecommendations! Published in 2018 at "Vaccine"
DOI: 10.1016/j.vaccine.2018.02.113
Abstract: BACKGROUND Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated with significant decrease in disease burden. However, disease caused by non-vaccine serotypes has increased. Safety and immunogenicity of 15-valent PCV (PCV15) containing serotypes included… read more here.
Keywords: safety; safety immunogenicity; pcv15; pcv13 ... See more keywords
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.08.048
Abstract: INTRODUCTION Streptococcus pneumoniae is a leading cause of bacteremia, bacterial pneumonia, and meningitis, and is associated with substantial morbidity and mortality, particularly in those under 2 years of age and those over 65 years of age. While… read more here.
Keywords: healthy adults; conjugate vaccine; valent pneumococcal; vaccine ... See more keywords
Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine.
Sign Up to like & getrecommendations! Published in 2020 at "Vaccine"
DOI: 10.1016/j.vaccine.2020.04.063
Abstract: Different schedules for pediatric use of the 13-valent pneumococcal conjugate vaccine (PCV-13) are recommended in different countries and the U.S. Advisory Committee on Immunization Practices (ACIP) has considered potential of changing from 3 primary doses… read more here.
Keywords: booster; antibody; conjugate vaccine; valent pneumococcal ... See more keywords